SirReal2 is a potent and selective small-molecule inhibitor of Sirtuin 2 (SIRT2), an enzyme involved in the regulation of cellular processes such as aging, metabolism, and inflammation. Its primary application lies in research settings, where it is used to probe the biological roles of SIRT2 in various disease models. In neurodegenerative disease research, SirReal2 has shown promise in models of Parkinson’s disease by reducing the accumulation of toxic protein aggregates, thereby protecting neurons. It modulates alpha-synuclein pathology through selective inhibition of SIRT2, making it a valuable tool for studying disease mechanisms and potential therapeutic pathways. Additionally, SirReal2 is used in cancer research due to the involvement of SIRT2 in cell cycle regulation and tumor suppression. By inhibiting SIRT2, it can alter the acetylation status of target proteins, influencing cell proliferation and apoptosis in certain cancer cell lines. Its high selectivity and cell permeability make SirReal2 a preferred compound for in vitro and in vivo studies aimed at validating SIRT2 as a drug target. It serves as a lead structure for the development of more advanced inhibitors with potential therapeutic applications in oncology, neurodegeneration, and metabolic disorders.